Evaluation of the incremental cost to the National Health Service of prescribing analogue insulin

• Published in: BMJ open 2011-01, Vol.1 (2), p.e000258-e000258
• Main Authors: Holden, Sarah E, Poole, Chris D, Morgan, Christopher Ll, Currie, Craig J
• Format: Article
• Language: English
• Subjects: Cost control; Diabetes; Health services; Insulin; Pharmacology and Therapeutics; Prescriptions
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2011-000258

IntroductionInsulin analogues have become increasingly popular despite their greater cost compared with human insulin. The aim of this study was to calculate the incremental cost to the National Health Service (NHS) of prescribing analogue insulin preparations instead of their human insulin alternatives.MethodsOpen-source data from the four UK prescription pricing agencies from 2000 to 2009 were analysed. Cost was adjusted for inflation and reported in UK pounds at 2010 prices.ResultsOver the 10-year period, the NHS spent a total of £2732 million on insulin. The total annual cost increased from £156 million to £359 million, an increase of 130%. The annual cost of analogue insulin increased from £18.2 million (12% of total insulin cost) to £305 million (85% of total insulin cost), whereas the cost of human insulin decreased from £131 million (84% of total insulin cost) to £51 million (14% of total insulin cost). If it is assumed that all patients using insulin analogues could have received human insulin instead, the overall incremental cost of analogue insulin was £625 million.ConclusionGiven the high marginal cost of analogue insulin, adherence to prescribing guidelines recommending the preferential use of human insulin would have resulted in considerable financial savings over the period.